Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): outcomes in firstline (1 L) R/m patients and updated safety and efficacy - Gillison, ML; Blumenschein, G; Fayette, J (J Clin Oncol, 2017)
et al.